Effects of indoleamine 2,3-dioxygenase inhibitor in non-Hodgkin lymphoma model mice

Peptide vaccines for hematological malignancies: a missed promise?

(2014) Monica Bocchia et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Adoptive T-cell therapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors

(2013) Hiroshi Fujiwara   INTERNATIONAL JOURNAL OF HEMATOLOGY

Indoleamine 2,3-dioxygenase expression and serum kynurenine concentrations in patients with diffuse large B-cell lymphoma

(2012) Soranobu Ninomiya et al.   LEUKEMIA & LYMPHOMA

Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives

(2011) J. Godin-Ethier et al.   CLINICAL CANCER RESEARCH

Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication

(2011) Sergio A. Quezada et al.   IMMUNOLOGICAL REVIEWS

Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP

(2010) Soranobu Ninomiya et al.   ANNALS OF HEMATOLOGY

The Absence of IDO Upregulates Type I IFN Production, Resulting in Suppression of Viral Replication in the Retrovirus-Infected Mouse

(2010) M. Hoshi et al.   JOURNAL OF IMMUNOLOGY

Serum concentration of L-kynurenine predicts the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP

(2009) Takeshi Yoshikawa et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma

(2009) Tomoko Inaba et al.   GYNECOLOGIC ONCOLOGY

Overexpression of Indoleamine 2,3-Dioxygenase in Human Endometrial Carcinoma Cells Induces Rapid Tumor Growth in a Mouse Xenograft Model

(2008) N. Yoshida et al.   CLINICAL CANCER RESEARCH

Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape

(2008) Jessica B. Katz et al.   IMMUNOLOGICAL REVIEWS